Viramune Launched In The UK For HIV

Boehringer Ingelheim has launched its non-nucleoside reversetranscriptase inhibitor Viramune (nevirapine) in the UK for use in combination therapies for patients with advanced HIV-1 infection.

Labeling for the drug notes that most clinical experience with Viramune is in combination with nucleoside analogs, and there are insufficient data on efficacy and subsequent use of triple combinations including protease inhibitors after nevirapine therapy. The net price of Viramune is L168 ($280.25) for 60 x 200mg tablets. The recommended dose is 200mg/day for the first 14 days, followed by 200mg twice-daily thereafter.